CME GROUP INC (CME) Fundamental Analysis & Valuation

NASDAQ:CME • US12572Q1058

Current stock price

305.11 USD
+8.17 (+2.75%)
At close:
306.54 USD
+1.43 (+0.47%)
After Hours:

This CME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. CME Profitability Analysis

1.1 Basic Checks

  • CME had positive earnings in the past year.
  • In the past year CME had a positive cash flow from operations.
  • CME had positive earnings in each of the past 5 years.
  • In the past 5 years CME always reported a positive cash flow from operatings.
CME Yearly Net Income VS EBIT VS OCF VS FCFCME Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

1.2 Ratios

  • With a Return On Assets value of 2.03%, CME perfoms like the industry average, outperforming 44.58% of the companies in the same industry.
  • The Return On Equity of CME (14.00%) is better than 71.25% of its industry peers.
  • CME has a better Return On Invested Capital (20.13%) than 95.83% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for CME is significantly above the industry average of 7.25%.
  • The last Return On Invested Capital (20.13%) for CME is above the 3 year average (18.73%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 2.03%
ROE 14%
ROIC 20.13%
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
CME Yearly ROA, ROE, ROICCME Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15 20

1.3 Margins

  • CME's Profit Margin of 32.81% is fine compared to the rest of the industry. CME outperforms 79.17% of its industry peers.
  • CME's Profit Margin has declined in the last couple of years.
  • CME has a Operating Margin of 81.31%. This is amongst the best in the industry. CME outperforms 98.75% of its industry peers.
  • CME's Operating Margin has improved in the last couple of years.
Industry RankSector Rank
OM 81.31%
PM (TTM) 32.81%
GM N/A
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
CME Yearly Profit, Operating, Gross MarginsCME Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60 80 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CME Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, CME has more shares outstanding
  • Compared to 5 years ago, CME has more shares outstanding
  • CME has a better debt/assets ratio than last year.
CME Yearly Shares OutstandingCME Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M
CME Yearly Total Debt VS Total AssetsCME Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • The Debt to FCF ratio of CME is 0.82, which is an excellent value as it means it would take CME, only 0.82 years of fcf income to pay off all of its debts.
  • With an excellent Debt to FCF ratio value of 0.82, CME belongs to the best of the industry, outperforming 88.75% of the companies in the same industry.
  • CME has a Debt/Equity ratio of 0.12. This is a healthy value indicating a solid balance between debt and equity.
  • CME has a Debt to Equity ratio of 0.12. This is in the better half of the industry: CME outperforms 79.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.82
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
CME Yearly LT Debt VS Equity VS FCFCME Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B 25B

2.3 Liquidity

  • CME has a Current Ratio of 1.03. This is a normal value and indicates that CME is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of CME (1.03) is comparable to the rest of the industry.
  • A Quick Ratio of 1.03 indicates that CME should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.03, CME perfoms like the industry average, outperforming 45.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
CME Yearly Current Assets VS Current LiabilitesCME Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. CME Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 9.26% over the past year.
  • The Earnings Per Share has been growing by 10.74% on average over the past years. This is quite good.
  • Looking at the last year, CME shows a very strong growth in Revenue. The Revenue has grown by 20.06%.
  • Measured over the past years, CME shows a quite strong growth in Revenue. The Revenue has been growing by 19.33% on average per year.
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%

3.2 Future

  • The Earnings Per Share is expected to grow by 4.89% on average over the next years.
  • The Revenue is expected to grow by 4.78% on average over the next years.
EPS Next Y7.52%
EPS Next 2Y6.94%
EPS Next 3Y7.53%
EPS Next 5Y4.89%
Revenue Next Year7.38%
Revenue Next 2Y6%
Revenue Next 3Y6.11%
Revenue Next 5Y4.78%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CME Yearly Revenue VS EstimatesCME Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B 10B
CME Yearly EPS VS EstimatesCME Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5 10

More info and screens

Find the best growth stocksShow best growing peers

2

4. CME Valuation Analysis

4.1 Price/Earnings Ratio

  • CME is valuated quite expensively with a Price/Earnings ratio of 27.22.
  • Based on the Price/Earnings ratio, CME is valued a bit more expensive than the industry average as 74.17% of the companies are valued more cheaply.
  • The average S&P500 Price/Earnings ratio is at 25.60. CME is around the same levels.
  • The Price/Forward Earnings ratio is 25.31, which means the current valuation is very expensive for CME.
  • CME's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. CME is more expensive than 65.42% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 22.84. CME is around the same levels.
Industry RankSector Rank
PE 27.22
Fwd PE 25.31
CME Price Earnings VS Forward Price EarningsCME Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, CME is valued cheaply inside the industry as 85.83% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of CME is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 26.09
EV/EBITDA 10.51
CME Per share dataCME EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CME does not grow enough to justify the current Price/Earnings ratio.
  • CME has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)3.62
PEG (5Y)2.53
EPS Next 2Y6.94%
EPS Next 3Y7.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. CME Dividend Analysis

5.1 Amount

  • CME has a Yearly Dividend Yield of 1.70%.
  • Compared to an average industry Dividend Yield of 6.85, CME is paying slightly less dividend.
  • CME's Dividend Yield is comparable with the S&P500 average which is at 1.88.
Industry RankSector Rank
Dividend Yield 1.7%

5.2 History

  • On average, the dividend of CME grows each year by 13.12%, which is quite nice.
  • CME has paid a dividend for at least 10 years, which is a reliable track record.
  • CME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.12%
Div Incr Years11
Div Non Decr Years11
CME Yearly Dividends per shareCME Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6 8 10

5.3 Sustainability

  • 97.81% of the earnings are spent on dividend by CME. This is not a sustainable payout ratio.
  • The dividend of CME is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP97.81%
EPS Next 2Y6.94%
EPS Next 3Y7.53%
CME Yearly Income VS Free CF VS DividendCME Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B 4B
CME Dividend Payout.CME Dividend Payout, showing the Payout Ratio.CME Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

CME Fundamentals: All Metrics, Ratios and Statistics

CME GROUP INC

NASDAQ:CME (4/2/2026, 8:15:57 PM)

After market: 306.54 +1.43 (+0.47%)

305.11

+8.17 (+2.75%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)02-04
Earnings (Next)04-22
Inst Owners92.17%
Inst Owner Change1.97%
Ins Owners0.24%
Ins Owner Change0.91%
Market Cap109.42B
Revenue(TTM)12.26B
Net Income(TTM)4.02B
Analysts71
Price Target316.44 (3.71%)
Short Float %1.56%
Short Ratio2.41
Dividend
Industry RankSector Rank
Dividend Yield 1.7%
Yearly Dividend10.92
Dividend Growth(5Y)13.12%
DP97.81%
Div Incr Years11
Div Non Decr Years11
Ex-Date03-10
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.37%
Min EPS beat(2)-0.02%
Max EPS beat(2)0.76%
EPS beat(4)2
Avg EPS beat(4)-0.03%
Min EPS beat(4)-1.28%
Max EPS beat(4)0.76%
EPS beat(8)5
Avg EPS beat(8)0.37%
EPS beat(12)9
Avg EPS beat(12)0.86%
EPS beat(16)13
Avg EPS beat(16)1.11%
Revenue beat(2)0
Avg Revenue beat(2)-0.79%
Min Revenue beat(2)-1.04%
Max Revenue beat(2)-0.54%
Revenue beat(4)0
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.72%
Max Revenue beat(4)-0.54%
Revenue beat(8)0
Avg Revenue beat(8)-0.91%
Revenue beat(12)2
Avg Revenue beat(12)-0.48%
Revenue beat(16)6
Avg Revenue beat(16)10.64%
PT rev (1m)2.7%
PT rev (3m)8.5%
EPS NQ rev (1m)2.35%
EPS NQ rev (3m)7.42%
EPS NY rev (1m)1.81%
EPS NY rev (3m)2.36%
Revenue NQ rev (1m)1.93%
Revenue NQ rev (3m)6.53%
Revenue NY rev (1m)0.7%
Revenue NY rev (3m)2.76%
Valuation
Industry RankSector Rank
PE 27.22
Fwd PE 25.31
P/S 8.93
P/FCF 26.09
P/OCF 25.58
P/B 3.81
P/tB N/A
EV/EBITDA 10.51
EPS(TTM)11.21
EY3.67%
EPS(NY)12.05
Fwd EY3.95%
FCF(TTM)11.69
FCFY3.83%
OCF(TTM)11.93
OCFY3.91%
SpS34.18
BVpS80.11
TBVpS-4.38
PEG (NY)3.62
PEG (5Y)2.53
Graham Number142.15
Profitability
Industry RankSector Rank
ROA 2.03%
ROE 14%
ROCE 26.14%
ROIC 20.13%
ROICexc 22.85%
ROICexgc 233.66%
OM 81.31%
PM (TTM) 32.81%
GM N/A
FCFM 34.21%
ROA(3y)2.34%
ROA(5y)1.97%
ROE(3y)13.02%
ROE(5y)11.7%
ROIC(3y)18.73%
ROIC(5y)14.69%
ROICexc(3y)20.74%
ROICexc(5y)16.19%
ROICexgc(3y)290.88%
ROICexgc(5y)224.49%
ROCE(3y)24.31%
ROCE(5y)19.07%
ROICexgc growth 3Y16.89%
ROICexgc growth 5Y15.23%
ROICexc growth 3Y24.21%
ROICexc growth 5Y29.59%
OM growth 3Y4.02%
OM growth 5Y7.87%
PM growth 3Y-3.77%
PM growth 5Y-4.62%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.12
Debt/FCF 0.82
Debt/EBITDA 0.33
Cap/Depr 25.23%
Cap/Sales 0.68%
Interest Coverage 73.5
Cash Conversion 41.54%
Profit Quality 104.29%
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z N/A
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)24.94%
Cap/Depr(5y)26.51%
Cap/Sales(3y)0.77%
Cap/Sales(5y)1.22%
Profit Quality(3y)104.54%
Profit Quality(5y)102.44%
High Growth Momentum
Growth
EPS 1Y (TTM)9.26%
EPS 3Y12%
EPS 5Y10.74%
EPS Q2Q%9.92%
EPS Next Y7.52%
EPS Next 2Y6.94%
EPS Next 3Y7.53%
EPS Next 5Y4.89%
Revenue 1Y (TTM)20.06%
Revenue growth 3Y19.31%
Revenue growth 5Y19.33%
Sales Q2Q%8.09%
Revenue Next Year7.38%
Revenue Next 2Y6%
Revenue Next 3Y6.11%
Revenue Next 5Y4.78%
EBIT growth 1Y24.41%
EBIT growth 3Y24.1%
EBIT growth 5Y28.72%
EBIT Next Year10.74%
EBIT Next 3Y9.04%
EBIT Next 5Y7.54%
FCF growth 1Y16.6%
FCF growth 3Y12.23%
FCF growth 5Y10.74%
OCF growth 1Y15.89%
OCF growth 3Y11.86%
OCF growth 5Y9.51%

CME GROUP INC / CME Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CME GROUP INC (CME) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CME.


What is the valuation status of CME GROUP INC (CME) stock?

ChartMill assigns a valuation rating of 2 / 10 to CME GROUP INC (CME). This can be considered as Overvalued.


What is the profitability of CME stock?

CME GROUP INC (CME) has a profitability rating of 7 / 10.


Can you provide the financial health for CME stock?

The financial health rating of CME GROUP INC (CME) is 5 / 10.


Can you provide the dividend sustainability for CME stock?

The dividend rating of CME GROUP INC (CME) is 4 / 10 and the dividend payout ratio is 97.81%.